Remove DNA Remove Genome Remove Genomics Remove Research
article thumbnail

Short reads, big impact: How genomics is revolutionising cancer research

pharmaphorum

Discover how genomics is transforming cancer research through the study of DNA, RNA, and ctDNA. Learn about the latest breakthroughs in the field in this insightful short read.

Genome 126
article thumbnail

Mysterious Viral DNA in Human Genome Linked With Psychiatric Disorders

AuroBlog - Aurous Healthcare Clinical Trials blog

Around 8% of human DNA is made up of genetic sequences acquired from ancient viruses. Our latest research suggests that some ancient viral DNA sequences in the […]

DNA 139
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130
article thumbnail

Uncovering packaging impurities with rAAV genome sequencing

Drug Discovery World

Join DDW for this exclusive free event, ‘ rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities ’. The post Uncovering packaging impurities with rAAV genome sequencing appeared first on Drug Discovery World (DDW). The event will be supported by Oxford Nanopore Technologies.

article thumbnail

How rAAV genome sequencing uncovers transgene integrity

Drug Discovery World

Join DDW for this exclusive free event, ‘ rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities ’. The post How rAAV genome sequencing uncovers transgene integrity appeared first on Drug Discovery World (DDW). The event will be supported by Oxford Nanopore Technologies.

Genome 52
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. In actuality, the protein-coding portion of our genome is comparable in identity and number with the humble fruit fly or worm.

RNA 52
article thumbnail

rAAV Genome sequencing uncovers transgene integrity and packaging impurities

Drug Discovery World

This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. The post rAAV Genome sequencing uncovers transgene integrity and packaging impurities appeared first on Drug Discovery World (DDW).